<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551924</url>
  </required_header>
  <id_info>
    <org_study_id>HR18034-101</org_study_id>
    <nct_id>NCT04551924</nct_id>
  </id_info>
  <brief_title>A Trial of HR18034 in Inguinal Hernia Repair</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety, Pharmacokinetics and Efficacy of HR18034 for Pain Management After Inguinal Hernia Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I, randomized, double-blind, comparator-controlled study to assess the safety, PK, and&#xD;
      efficacy of single postsurgical application of HR18034 compared with Naropin®&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>To maintain objectiveness, the study drug will be managed and administered by an independent unblinded team. Subjects, investigators, and all other site staff who directly interact with subjects, evaluate safety and efficacy, and collect subject data, will remain blinded and must not communicate or discuss any study information with the unblinded team.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of SAEs and treatment-related severe AEs</measure>
    <time_frame>14 days</time_frame>
    <description>Safety and tolerability:</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity assessed using an 11-point NPRS ranging</measure>
    <time_frame>Baseline till 168 hours post IP administration</time_frame>
    <description>11-point Numercal Pain Rating Scale ranging from a score of 0 to 10. Pain-free defined as an NPRS of 0 or 1. Worst imaginable pain defined as an NPRS of 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of NPRS</measure>
    <time_frame>For time periods 0-12, 0-24, 0-36, 0-48, 0-72, and 0-96 hours</time_frame>
    <description>AUC of NPRS for time periods 0-12, 0-24, 0-36, 0-48, 0-72, and 0-96 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of the method of pain control</measure>
    <time_frame>24 hours post IP administration till 168 hours post IP administration</time_frame>
    <description>Patient Global Assessment ranging from a score of 0 to 10. Satisfaction defined as a scale of 10, dissatisfaction defined as a scale of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of pain-free subjects at scheduled timepoints.</measure>
    <time_frame>Baseline till 168 hours post IP administration</time_frame>
    <description>Pain-free defined as an NPRS of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who used no rescue opioid analgesic</measure>
    <time_frame>Baseline till 168 hours post IP administration</time_frame>
    <description>Proportion of subjects who used no rescue opioid analgesic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily rescue analgesic consumption</measure>
    <time_frame>Baseline till 168 hours post IP administration</time_frame>
    <description>Average daily rescue analgesic consumption through 24, 48, 72 and 96 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first postoperative use of rescue opioid analgesics</measure>
    <time_frame>Baseline till 168 hours post IP administration</time_frame>
    <description>Time to the first postoperative use of rescue opioid analgesics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Cmax</measure>
    <time_frame>Baseline till 168 hours post IP administration</time_frame>
    <description>Maximum blood concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound assessment by Wound healing and status score</measure>
    <time_frame>Day 1 through Day 14</time_frame>
    <description>The surgical site will be examined by the investigator using Wound healing and status score. Wound healing and status score ranging from a score of 0 to 4，Good defined as a scale of 0. Worst defined as a scale of 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK AUC</measure>
    <time_frame>Baseline till 168 hours post IP administration</time_frame>
    <description>Area under the blood concentration-time curve (AUC)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Inguinal Hernia Repair</condition>
  <arm_group>
    <arm_group_label>dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naropin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naronpin injection contains ropivacaine HCl. Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR18034</intervention_name>
    <description>HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome</description>
    <arm_group_label>dose 1</arm_group_label>
    <arm_group_label>dose 2</arm_group_label>
    <arm_group_label>dose 3</arm_group_label>
    <arm_group_label>dose 4</arm_group_label>
    <other_name>subjects will receive HR18034.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naropin</intervention_name>
    <description>Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg [0.5%, 5mg/mL] x 30mL</description>
    <arm_group_label>Naropin</arm_group_label>
    <other_name>Naropin, 0.5% Injectable Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Able and willing to provide a written informed consent 2、Male or female between 18 and 70&#xD;
        years of age 3、Scheduled to undergo a primary, inguinal hernia repair with mesh, and be&#xD;
        able to use the anesthesia regimen 4、Meet the body mass 5、Conform to the ASA Physical&#xD;
        Status Classification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant abnormal clinical laboratory test value&#xD;
&#xD;
          2. Subjects with poor blood pressure control after medication&#xD;
&#xD;
          3. Subjects with atrioventricular block or cardiac insufficiency&#xD;
&#xD;
          4. Subjects with a history of myocardial infarction or unstable angina pectoris&#xD;
&#xD;
          5. Subjects with a history of ischemic stroke or transient ischemic attack&#xD;
&#xD;
          6. Combination of other pain conditions that may affect postoperative pain assessment&#xD;
&#xD;
          7. Allergic to a drug ingredient or component&#xD;
&#xD;
          8. Persistent or recurrent nausea and/or vomiting due to other etiologies, including, but&#xD;
             not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer&#xD;
&#xD;
          9. History of alcohol abuse or prescription and/or illicit drug abuse within 1 years&#xD;
&#xD;
         10. Subjects with special diets (including tobacco, grapefruit and caffeine)&#xD;
&#xD;
         11. Positive results on the urine drug screen or alcohol breath test indicative of illicit&#xD;
             drug or alcohol abuse.&#xD;
&#xD;
         12. History of human immunodeficiency virus (HIV), hepatitis C, syphilis antibody，or&#xD;
             hepatitis B.&#xD;
&#xD;
         13. Use of any of the following medications within 14 days or as specified prior to the&#xD;
             study surgical procedure:&#xD;
&#xD;
         14. Have had an inguinal hernia repair in the last 3 months before the study surgical&#xD;
             procedure or presents with bilateral or recurrent inguinal hernia, other hernia&#xD;
             presentations, or hernias with a large scrotal component that would be difficult to&#xD;
             reduce surgically&#xD;
&#xD;
         15. Participated in clinical trials of other drugs (received experimental drugs)&#xD;
&#xD;
         16. History or clinical manifestations of significant renal, hepatic, gastrointestinal,&#xD;
             cardiovascular, metabolic, neurologic, psychiatric, or other condition.&#xD;
&#xD;
         17. Pregnant or nursing women&#xD;
&#xD;
         18. No birth control during the specified period of time&#xD;
&#xD;
         19. The inestigators determined that other conditions were inappropriate for participation&#xD;
             in this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weidong Mi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weidong Mi, PhD</last_name>
    <phone>010-66937116</phone>
    <email>wwdd1962@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong Mi, PhD</last_name>
      <phone>010-66937116</phone>
      <email>wwdd1962@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

